No Photo Available

Last Update

2017-01-22T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Lloyd Kasper?

Dr. Lloyd H. Kasper MD

Direct Phone: (866) ***-****       

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Geisel School of Medicine at Dartmouth

1 Medical Center Drive

Lebanon, New Hampshire 03756

United States

Find other employees at this company (398)

Background Information

Employment History

Director

Dartmouth-Hitchcock Medical Center

Affiliations

Co-Founder
Symbiotix Biotherapies Inc

Advisory Board Member
Prime Inc

Co-Founder
Symbiotix Inc

Education

M.D.

MD

Dartmouth University

Web References (45 Total References)


Scientific Advisory Board – Symbiotix Biotherapies, Inc.

symbiotix-bio.com [cached]

Lloyd Kasper, M.D. - Founder and Director Professor of Medicine, Microbiology and Immunology, Geisel School of Medicine at Dartmouth College


Founding Team – Symbiotix Biotherapies, Inc.

symbiotix-bio.com [cached]

Lloyd Kasper, M.D.

...
Lloyd Kasper, M.D.,
Professor of Medicine, Microbiology and Immunology, Geisel School of Medicine at Dartmouth College
Dr. Lloyd Kasper has been actively involved for many years in basic and applied neuroimmunology supported by research grants from the National Institutes of Health, March of Dimes, National Multiple Sclerosis Society and industry. He has published extensively on the immunology of the obligate intracellular parasite, Toxoplasma gondii, having identified critical antigens and immune pathways that are involved in disease pathogenesis. Some of these parasite antigens have been patented and extensively utilized by industry to develop neonatal screening for toxoplasma infection in the US and Europe. He established and was the long-time Director of the Dartmouth MS Center that serves an MS population of >1500 patients in northern New England. His basic research interests in MS are related primarily to understanding disease pathogenesis, the role of specific regulatory populations elicited by current and novel therapies, and the role of the gut microbiome in the regulation of CNS demyelination.
The National Multiple Sclerosis Society (NMSS), NIH and industry have awarded multiple grants to him to support this work. Dr. Kasper has been PI and co-investigator for NIH supported clinical trials in MS including anti-CD40L (CD154), CombiRx, estriol plus glatiramer and CTLA4-Ig. He has served as an advisor for industry (Biogen Idec, Novartis, Genzyme, Sanofi, Teva Neuroscience, Mederex, Centocor, Bayer Healthcare, EMD Serono, ONO Pharmaceuticals, Genentech) on clinical and research protocol development for a number of clinical trials in MS including rituximab, ocrilizumab, alumtuzumab, daclizumab, ONO-4641, anti-IL12p40, lacquinimod, anti-CD40, CTLA-4Ig, TACI-Ig, and FTY-720. He has served in ad hoc, permanent and chairperson positions on NIH and NMSS study section. He has organized three Keystone symposia including Opportunistic Infections in AIDS, Translational Medicine in Autoimmunity and most recently the Role of the Gut Microbiome: Effector/Regulatory Networks that was held in February 2013. Dr. Kasper has authored over 175 research and clinical articles related to his basic research interests in immunology and clinical expertise in multiple sclerosis.


Lloyd H Kasper

www.psychosomatic.org [cached]

Dr. Lloyd Kasper

...
Lloyd H Kasper, MD
Dr. Lloyd Kasper is a Professor of Immunology/Microbiology and Medicine at Geisel School of Medicine where he has been actively involved in basic and applied immunology supported by research grants from the National Institutes of Health, March of Dimes, National Multiple Sclerosis Society and industry. He established and directed the Dartmouth MS Center for over 20 years. His basic research interests are related to understanding immunopathogenesis of CNS demyelinating disease, the role of specific immune regulatory populations in disease control and the role of the gut microbiome in CNS demyelination. Dr. Kasper has authored over 175 research and clinical articles related to these interests. He has been the primary organizer for several Keystone Symposia most recently the Microbiome: Effector/Regulatory Networks. When not doing science at Dartmouth, Kasper can be found painting in his studio in Taos, New Mexico.


Symbiotix Biotherapies Announces $2.3 million Award from NIH’s National Institute of Allergy and Infectious Diseases (NIAID) – Symbiotix Biotherapies, Inc.

symbiotix-bio.com [cached]

Symbiotix' lead clinical candidate, Polysaccharide A (PSA), is the first molecule to emerge from the microbiome and the $2.3 million NIH award enables the completion of key translational studies and production of material needed to take into human clinical trials as a novel treatment for multiple sclerosis (MS), said Prof. Lloyd Kasper, Professor of Medicine, Microbiology and Immunology at Geisel School of Medicine at Dartmouth College, and Co-Founder of Symbiotix.

PSA is a first-in-class oral therapy that works through a novel mechanism of action related to activation of regulatory T cells, which exert an anti-inflammatory effect through the production of IL-10.
"Current FDA-approved therapies for multiple sclerosis offer only partial benefit for reduction of relapses and time to disability. However, all of these FDA-approved treatments have side effects some of which can be rather profound," said Prof. Kasper. "We are developing PSA as a safe and effective new oral therapy for the over 500,000 US patients with multiple sclerosis.


The study adds more evidence that ...

www.msdiscovery.org [cached]

The study adds more evidence that "bacteria have the capacity in and of themselves to modulate the immune system and make it respond in a positive way," said Lloyd Kasper, M.D., an immunologist and neurologist at Geisel School of Medicine at Dartmouth College in New Hampshire, who was not involved in the study.

The experiments did not use an MS model, but in an interview with the MS Discovery Forum (MSDF), Kasper speculated that the bacteria metabolites might have a similar effect in mouse models of MS. Three years ago, Kasper's team reported that a molecule on the surface of one common species of gut bacteria (Bacteroides fragilis) protected against central nervous system demyelinating disease in two experimental autoimmune encephalomyelitis mouse models, apparently by turning on Tregs, both prophylactically and therapeutically (Ochoa-Repáraz, et al., 2010).
...
Similar caveats apply to all work on how the microbiome affects immune function, Kasper and Mazmanian said.

Similar Profiles

Other People with this Name

Other people with the name Kasper

Debi Kasper
Healthcare IP

Thomas Kasper
Reid & Riege , P.C.

Megan Kasper
Benjamin Foods

Peggy Kasper
Presence Health

Gordon Kasper
The SAVO Group

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory